$ALXO

ALX Oncology (Nasdaq: ALXO) reported Q2 2026 results and a corporate update. Cash, cash equivalents and investments were $153.4 million as of June 30, 2026. R&D fell to $13.1 million from $18.0 million year over year, and GAAP net loss was $18.0 million ($0.13/share). The company said ASPEN-09-Breast topline data from 80 patients is expected mid-2027, and ALX2004 safety data is expected in 2H 2026.

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update – On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in com

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001810182 false 0001810182 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001810182 0001810182 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,

ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001810182 false 0001810182 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

MarketBeat compares ALX Oncology (ALXO) and Medicus Pharma (MDCX) on earnings, risk, valuation, profitability, ownership and analyst ratings. ALXO has a consensus target of $4.60 (134.7% upside) versus MDCX’s $9.00 (2,817.3%). ALXO is described as more affordable by P/E; ALXO beta is 0.41 and institutional ownership 98%.

ALX Oncology Holdings Inc. (ALXO) has filed its definitive proxy statement (DEF 14A) for its 2026 annual stockholders' meeting, to be held virtually on June 10, 2026. Stockholders will vote on the election of three Class III directors, an advisory "say-on-pay" resolution for named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm. The filing also details executive compensation, including base salaries, cash incentives, and equity awards, along with information on director independence, board structure, and related-party transactions.

ALX Oncology Holdings Inc is

ALX Oncology updated on its clinical-stage programs, evorpacept and ALX2004, at the J.P. Morgan conference. The company highlighted strong Aspen-06 subset results for evorpacept in HER2-retained gastric cancer, prompting a focus on HER2-positive breast cancer and multiple myeloma. ALX2004, an EGFR ADC, showed favorable preclinical data and is in Phase 1 dose escalation across multiple tumor types.

ALX Oncology will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Jason Lettmann and CMO Barbara Klencke will deliver a corporate presentation on January 15, 2026, which will be accessible via webcast. The company focuses on developing novel therapies, including evorpacept and ALX2004, to treat various cancers.